

TG THERAPEUTICS, INC.  
Form 8-K  
December 07, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **December 6, 2015**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**3 Columbus Circle, 15<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..                   Written communications pursuant to Rule 425 under the Securities Act.
- ..                   Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01. Other Events.**

On December 6, and December 7, 2015, TG Therapeutics, Inc. issued press releases announcing certain data regarding its clinical studies of TG-1101 in combination with TGR-1202, TGR-1202 in combination with obinutuzumab, TGR-1202 as a single agent, and a pre-clinical data presentation on the combination of TGR-1202 and proteasome inhibitors, respectively. Copies of the press releases are being filed as Exhibits 99.1, 99.2 and 99.3 and incorporated in this Item by reference.

**Item 9.01 Financial Statements And Exhibits.**

(d) Exhibits.

99.1 Press Release, dated December 6, 2015.

99.2 Press Release, dated December 7, 2015.

99.3 Press Release, dated December 7, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**

(Registrant)

Date: December 7, 2015

By: /s/ Sean A. Power

Sean A. Power

Chief Financial Officer

INDEX TO EXHIBITS

**Exhibit  
Number Description**

- 99.1 Press Release, dated December 6, 2015.
- 99.2 Press Release, dated December 7, 2015.
- 99.3 Press Release, dated December 7, 2015.